Zymeworks (ZYME) EBITDA Margin (2021 - 2026)

Zymeworks has disclosed EBITDA Margin across 6 years of filings, most recently posting 1854.15% for Q1 2026.

• EBITDA Margin for Q1 2026 came in at 1854.15%, down 114157.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 130.73% (up 6256.0% YoY), and the FY2025 annual result was 75.74%, up 8552.0% from the prior year.
• EBITDA Margin came in at 1854.15% for Q1 2026 at Zymeworks, down from 1639.68% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 95.21% in Q4 2022 to a low of 3790.45% in Q1 2022.
• The 5-year median for EBITDA Margin is 326.76% (2024), against an average of 771.15%.
• Across the five-year window, EBITDA Margin jumped 372402 bps in 2023 and tumbled 156086 bps in 2025, its largest moves.
• Zymeworks' EBITDA Margin stood at 95.21% in 2022, then plunged by 179 bps to 75.55% in 2023, then declined by 4 bps to 78.82% in 2024, then tumbled by 1980 bps to 1639.68% in 2025, then declined by 13 bps to 1854.15% in 2026.
• The last three EBITDA Margin figures came in at 1854.15% (Q1 2026), 1639.68% (Q4 2025), and 77.25% (Q3 2025), per Business Quant data.